Specifically, an inhibitor named 18 097 reduces mRNA stability and expression of PPARγ and C/EBP-α/β by inhibiting FTO, leading to decreased lipid uptake and oxidation in cancer cells, and effectively restraining breast cancer growth and lung metastasis in vivo [150]. Here, FTO is linked to cancer.